Back to search

Peptide record

TPDB41196

DKH Anticancer standard
15 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB41196
DKH
Anticancer
Cancer-related peptides
CancerPPD 2.0
standard
No
A 15-aa standard natural anticancer peptide sequence curated from CancerPPD 2.0, with an available 3D structural model.
C-terminal: Amidation
Sequence
GLLDLLKLLLHAAGW-NH2
Physicochemical Analysis
C79H129N19O18
RNCEQIMFPSTYV
L
1633.01
7.81
2
1
10
+0
-2.91
1.193
195.33
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
5500
336.80
0
Residue Composition
number
2
A
0
R
0
N
1
D
0
C
0
E
0
Q
2
G
1
H
0
I
7
L
1
K
0
M
0
F
0
P
0
S
0
T
1
W
0
Y
0
V
Amino Acid Distribution
A: 2 R: 0 N: 0 D: 1 C: 0 E: 0 Q: 0 G: 2 H: 1 I: 0 L: 7 K: 1 M: 0 F: 0 P: 0 S: 0 T: 0 W: 1 Y: 0 V: 0
Chemical Descriptors
15
C79H129N19O18
1633.01
7.81
+0
-2.91
1.193
Amidation
L
Linear
Free
Anticancer
Synthetic
Evidence Records 3 records
Evidence 1 Activity

Activity

IC50
IC50 = 3.45 ± 0.07 µM
Anticancer
3.45

Target

Breast Cancer
HMLER
Breast

Assay & Model

MTT assay
72-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2022

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50 = 2.80 ± 0.28 µM
Anticancer
2.80

Target

Breast Cancer
HMLER-shEcad
Breast

Assay & Model

MTT assay
72-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2022
Evidence 3 Activity

Activity

IC50
IC50 = 21.13 ± 3.01 µM
Anticancer
21.13

Target

Bone Cancer
U-2 OS
Bone

Assay & Model

MTT assay
72-h

Source & Reference

CancerPPD 2.0
CancerPPD2
2022